Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Dollar Holds Firm as Strong U.S. Data, Fed Expectations and Global Central Bank Moves Shape Markets 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Pfizer Inc.’s planned delivery of critical new medicines, such as respiratory syncytial virus (RSV) vaccine, to low-income nations, is likely to be delayed by several years due to several issues.
According to global health officials, Pfizer has not yet taken some of the necessary actions to make the vaccine accessible in developing nations.
They include getting the shot approved by the WHO and by nonprofit organizations that finance purchases in low-income countries, such as the global vaccine alliance Gavi.
Furthermore, the health agency prefers syringes that are automatically disabled after one injection for safety reasons to prevent reuse, but Pfizer's RSV vaccine is not made for those syringes.
Additionally, the RSV shot is only presently offered in single-dose vials. Multi-dose vials are frequently utilized in situations with less resources since they are less expensive and easier to distribute.
Preservatives must be added to multi-dose vials, therefore the manufacturer must do further tests to make sure there will be no impact on the vaccine's safety or effectiveness.
The vaccine will need a different delivery system to be used in developing countries in Africa and Asia, including alternative packaging and syringes.
Preparations for those modifications are just beginning, according to the World Health Organization.
Pfizer committed to more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. The company says it wants to shorten a timeline in which poorer countries often get vaccines many years after they are available elsewhere.
The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the RSV vaccine in poorer countries, where RSV, a common cold-like virus, is much more likely to be lethal for very young children.
Pfizer's maternal RSV vaccine is expected to be approved for use in pregnant women in August in the US and several months later in Europe. Its peak sales forecast is more than $2 billion annually, together with the maternal vaccine and an RSV shot for older adults.
